Table 1.
Patient demographics and transplant variables
| Allogeneic HCT cohort (n = 22) | Autologous HCT cohort (n = 41) | |
|---|---|---|
| Median (range) age at HCT, years | 49 (25–59) | 54 (40–60) |
| Median time (range) from diagnosis to HCT, days | 269 (141–637) | 279 (144–990) |
| Immunoglobulin subtype | ||
| IgG | 12 (55%) | 15 (37%) |
| IgA | 3 (13%) | 11 (27%) |
| IgD | 0 | 1 (2%) |
| Light chain only | 7 (32%) | 12 (29%) |
| Non-secretory | 0 | 2 (5%) |
| Durie–Salmon staging | ||
| 1A | 1 (4%) | 1 (2%) |
| 2A | 2 (9%) | 9 (22%) |
| 3A | 14 (64%) | 24 (59%) |
| 3B | 5 (23%) | 7 (17%) |
| Cytogenetics/FISH | ||
| High-risk | 7 (32%) | 5 (21% = 5/24) |
| Not available | 0 | 17 |
| Disease status at HCT | ||
| sCR | 6 (27%) | 13 (32%) |
| CR | 4 (18%) | 13 (32%) |
| VGPR | 12 (55%) | 15 (36%) |
| Number of prior therapy | 1 (100%) | 1 (100%) |
| Prior therapya | ||
| Lenalidomide-based | 2 (9%) | 8 (19%) |
| Bortezomib-basedb | 9 (41%) | 16 (39%) |
| Both lenalidomide and bortezomib | 11 (50%) | 4 (10%) |
| Other regimens | 0 | 13 (32%) |
| Donor relation | ||
| Related | 9 (41%) | — |
| Unrelatedc | 13 (59%) | — |
| Donor/recipient gender matching | (Male/female = 25/16) | |
| Female/female | 5 (23%) | — |
| Female/male | 4 (18%) | — |
| Male/female | 6 (27%) | — |
| Male/male | 7 (32%) | — |
| Donor/recipient CMV | ||
| Negative/negative | 6 (27%) | — |
| Negative/positive | 7 (32%) | — |
| Positive/negative | 3 (14%) | — |
| Positive/positive | 6 (27%) | — |
| GVHD prophylaxis | ||
| Tacrolimus/MTX | 8 (36%) | — |
| Tacrolimus/mycophenolate mofetil | 6 (28%) | — |
| Tacrolimus/sirolimus | 8 (36%) | — |
| Median CD34 (range) cell dose (× 106/kg)d | 6.38 (1.43–10.65) | 3.53 (2.02–30.06) |
| Median Karnofsky performance status (range) at HCT | 90 (80–100) | 90 (70–100) |
Abbreviations: HCT = hematopoietic cell transplantation; sCR = stringent CR; VGPR, very good partial response
a
All patients received dexamethasone.
b
Two patients received liposomal doxorubicin containing triplet therapy and two others received CY-containing triplet therapy.
c
One donor was mismatched at DQ locus (9/10 matched)
d
Recipient who received 1.43 × 106 CD34+ cells/kg later received stem cell boost.